RxDoctor Payments DataLook up a doctor →

Gena Volas Redd, MD

Hematology & Oncology · Marietta, GANPI 1104804798

Payments from drug & device makers

$741,734in general payments, 2019–2025

Across 257 payments — averaging $2886.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$400K
  • Genentech, Inc.$105K
  • Novartis$91K
  • AstraZeneca$68K
  • Pfizer$32K
  • Novocure GmbH$25K
  • plus $20K from 30 others

What the payments were for

  • Consulting fees$19,06825%
  • Speaking & faculty fees$44,33058%
  • Travel & lodging$8,73411%
  • Food & beverage$4,5036%
  • Education$3450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$741,734 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$87,780
Medicare patients
483
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib43$661,213
RevlimidLenalidomide30$599,291
ImbruvicaIbrutinib30$409,395
TruqapCapivasertib18$377,645
VerzenioAbemaciclib22$367,277
PomalystPomalidomide11$257,369
Lenalidomide15$234,963
TasignaNilotinib Hcl13$191,132
BrukinsaZanubrutinib12$145,984
EliquisApixaban120$96,937
XareltoRivaroxaban50$40,241
CreonLipase/Protease/Amylase21$31,667
Letrozole203$3,859
Anastrozole233$3,681
Fentanyl40$3,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$31,820$758,150163 claims
Bristol Myers SquibbRevlimid$33$599,29130 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$42$409,39530 claims
AstraZenecaTruqap$68,350$377,64518 claims
Lilly USA, LLCVerzenio$5,127$367,27722 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$138$257,36911 claims
NovartisTasigna$91,094$191,13213 claims
Beigene USA, Inc.Brukinsa$24$145,98412 claims
Johnson & JohnsonXarelto$28$40,24150 claims
AbbVieCreon$21$31,66721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →